AI Image
Caribou Biosciences, maker of CAR-T therapy for lymphoma, to shutter
STAT • • business
Key Points:
- Caribou Biosciences is shutting down due to an inability to secure funding for a late-stage clinical trial of its off-the-shelf CAR-T therapy for lymphoma.
- The biotech, founded from Nobel laureate Jennifer Doudna's CRISPR research lab, will halt development of its two CRISPR-based CAR-T therapies, including vispa-cel for advanced B-cell non-Hodgkin lymphoma.
- Despite successfully working with the FDA to finalize a Phase 3 trial design for vispa-cel, Caribou was unable to raise the necessary funds to conduct the study.
- CEO Rachel Haurwitz confirmed that financial challenges were the primary reason for discontinuing the clinical development program.
